REGULATION OF EMERGENCY BIO-MANUFACTURING DEPLOYMENT IN JAPAN

1. INTRODUCTION

Emergency bio-manufacturing deployment refers to the rapid mobilisation, expansion or conversion of biotechnology and pharmaceutical manufacturing facilities during public health emergencies, infectious disease outbreaks, pandemics and other biological crises. It may involve the accelerated production of vaccines, biological medicines, diagnostic products, therapeutic proteins and other essential medical supplies.

In Japan, emergency bio-manufacturing is governed by a combination of pharmaceutical legislation, public health laws, emergency preparedness frameworks, manufacturing quality requirements, environmental regulations and government procurement mechanisms.

The principal objective is to accelerate the availability of essential medical products without compromising product safety, manufacturing quality, patient protection and regulatory accountability. Japan's regulatory framework therefore seeks to balance emergency production capacity with strict oversight by the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

2. PRINCIPAL LEGAL FRAMEWORK IN JAPAN

A. PHARMACEUTICALS AND MEDICAL DEVICES ACT (PMD ACT)

The Pharmaceuticals and Medical Devices Act is the principal legislation regulating pharmaceutical products, biologics, medical devices and manufacturing activities in Japan.

Its regulatory requirements include:

Marketing authorisation for pharmaceutical products, subject to applicable statutory exceptions and special pathways.

Licensing or registration requirements for relevant manufacturing activities.

Good Manufacturing Practice (GMP) compliance.

Quality assurance and product-safety obligations.

Post-marketing safety monitoring and adverse-event reporting.

Regulatory inspections and corrective measures.

Emergency circumstances do not automatically exempt manufacturers from essential safety and quality obligations.

B. INFECTIOUS DISEASES CONTROL ACT

The Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases establishes Japan's framework for preventing and controlling infectious diseases.

It supports governmental public health responses, coordination and implementation of disease-control measures. Its relevance to emergency manufacturing arises from the need to secure essential vaccines, medicines and diagnostic products during infectious disease emergencies.

C. ACT ON SPECIAL MEASURES FOR PANDEMIC INFLUENZA AND NEW INFECTIOUS DISEASES PREPAREDNESS AND RESPONSE

This legislation provides a framework for governmental preparedness and responses to serious infectious disease emergencies.

It supports coordinated public health measures, government planning and cooperation between national and local authorities. It also provides an institutional basis for securing essential medical supplies during major infectious disease emergencies.

D. BIOLOGICAL SAFETY AND ENVIRONMENTAL REGULATION

Emergency bio-manufacturing facilities must comply with applicable biological safety, occupational safety, waste-management and environmental requirements.

The Act on the Conservation and Sustainable Use of Biological Diversity through Regulations on the Use of Living Modified Organisms (Cartagena Act) is relevant where manufacturing or research activities involve living modified organisms within its scope.

3. EMERGENCY APPROVAL AND ACCELERATED MANUFACTURING

A. EMERGENCY APPROVAL UNDER ARTICLE 14-2-2

The 2022 amendment to the PMD Act introduced an emergency approval mechanism under Article 14-2-2.

This mechanism permits emergency approval where:

The product is urgently required to prevent the spread of a serious disease or expansion of public health damage.

No appropriate alternative means of prevention or treatment exists.

Safety has been confirmed.

Efficacy can reasonably be estimated from available scientific evidence.

Emergency approval may be granted subject to conditions and a time limit not exceeding two years, with a possible extension of up to one year.

Certain inspections and documentation requirements may be deferred, but subsequent regulatory verification remains important.

B. SPECIAL APPROVAL UNDER ARTICLE 14-3

Special approval for emergency use provides an accelerated route for qualifying products already authorised overseas under the statutory requirements.

This mechanism was used during COVID-19, including for remdesivir in May 2020.

C. GOVERNMENT SUPPORT FOR MANUFACTURING CAPACITY

Japan may support domestic manufacturing through research funding, strategic procurement, industrial investment and public-private partnerships. The Japan Agency for Medical Research and Development (AMED) contributes to research and development initiatives.

4. CASE LAWS AND JUDICIAL PRECEDENTS

There is no established Japanese Supreme Court judgment specifically addressing emergency bio-manufacturing deployment. The following decisions provide relevant direct or analogous principles.

1. Iressa Drug Litigation (2013, Supreme Court of Japan)

Direct authority on pharmaceutical product liability.

The litigation concerned lung cancer medication and alleged inadequate warnings about serious adverse effects. The Supreme Court examined pharmaceutical manufacturers' responsibility for foreseeable risks and product warnings. It is relevant to emergency products because accelerated deployment does not eliminate manufacturers' safety communication responsibilities.

2. Chloroquine Drug Injury Litigation (Supreme Court, 23 June 1995)

Direct authority on pharmaceutical regulatory responsibility.

The Court considered governmental responsibility concerning pharmaceutical approvals and failure to exercise regulatory powers. It provides important principles for assessing whether regulatory authorities have acted reasonably in protecting public health.

3. HIV Blood Products Litigation (Supreme Court, 3 March 2008)

Direct authority on criminal responsibility in pharmaceutical safety.

The Supreme Court upheld criminal responsibility in connection with the administration of HIV-contaminated blood products. The case demonstrates that serious professional failures in biological-product safety can attract criminal liability.

4. MMR Vaccine Litigation (Osaka District Court, 13 March 2003; Osaka High Court, 20 April 2006)

Direct authority on vaccine manufacturing and regulatory supervision.

The litigation concerned the manufacture and distribution of vaccines using an unapproved vaccine strain and associated safety consequences. It highlights the importance of manufacturing authorisation, regulatory supervision and product quality.

5. Smallpox Vaccination Injury Case (Supreme Court, 19 April 1991)

Analogous authority.

The Court addressed serious injuries following vaccination and the significance of identifying contraindications. Its reasoning is relevant to ensuring that emergency deployment procedures preserve appropriate patient-safety safeguards.

6. Vaccination Injury Litigation (Supreme Court, 12 June 1998)

Analogous authority.

The Court considered governmental liability arising from vaccination-related injuries and remanded part of the dispute for further proceedings. It provides guidance on public-authority responsibility and the assessment of vaccination-related harm.

5. CORPORATE LIABILITY AND REGULATORY ENFORCEMENT

Manufacturers may face administrative sanctions, civil liability and criminal consequences for:

Manufacturing without required authorisation.

Breaching GMP requirements.

Distributing unsafe or defective products.

Concealing adverse-event information.

Providing inaccurate regulatory documentation.

Failing to comply with product recalls.

Violating applicable biological safety requirements.

The MHLW may exercise statutory powers to require corrective measures, suspend manufacturing or distribution, and order recalls where legally justified.

6. PRACTICAL COMPLIANCE REQUIREMENTS

Emergency bio-manufacturing operators should maintain:

Valid manufacturing licences and applicable registrations.

Appropriate emergency product approvals.

Documented quality-management systems.

GMP compliance and inspection records.

Product traceability and batch documentation.

Adverse-event reporting procedures.

Occupational and biological safety controls.

Environmental and waste-management compliance.

Emergency supply-chain continuity plans.

Post-approval studies and regulatory reporting.

7. CONCLUSION

Japan regulates emergency bio-manufacturing deployment through the PMD Act, emergency approval provisions, infectious disease legislation, manufacturing quality standards and biological safety requirements.

The introduction of Article 14-2-2 in 2022 strengthened Japan's capacity to accelerate the approval of essential pharmaceutical and biological products during serious public health emergencies. However, emergency approval does not remove the fundamental responsibilities of manufacturers to maintain safety, quality, transparency and regulatory compliance.

The relevant Japanese judicial precedents demonstrate that manufacturers and government authorities may face liability for defective products, inadequate warnings, unsafe biological products and failures of regulatory supervision. Accordingly, Japan's approach seeks to combine rapid manufacturing mobilisation with continuing public health protection and legal accountability.